Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems
This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.
Authors
- Reshma Ramachandran (ORCID: https://orcid.org/0000-0003-3845-3606)
- Shaimaa Elshafie (ORCID: https://orcid.org/0000-0001-7279-4418)
- Joseph S. Ross (ORCID: https://orcid.org/0000-0002-9218-3320)
- Joshua David Wallach (ORCID: https://orcid.org/0000-0002-2816-6905)
- Erfan Taherifard (ORCID: https://orcid.org/0000-0002-9101-0321)
- Rou-Zhen Chen
Institutions
- Yale New Haven Hospital (US)
- Emory University (US)
- Yale University (US)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1001/jamainternmed.2026.5774
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00